Internet-Behavioral Cough Suppression Therapy
Cough, Chronic Disease
About this trial
This is an interventional treatment trial for Cough focused on measuring refractory chronic cough, behavioral cough suppression therapy
Eligibility Criteria
Inclusion Criteria: No barriers to using a computer or smartphone (e.g., no significant fine motor or visual problems). Internet and e-mail access and the ability to use it. Suffering from a cough lasting at least eight weeks that is: Largely unproductive (cough up no more than a few teaspoons worth of clear or white sputum or mucus in a 24-hour period). Report of cough triggered by identifiable stimuli including and not limited to any combination of the following: cold air, talking, laughing, taking a deep breath, exercise, crumbly foods, strong smells or odors, fumes from paint or cleaning sprays. Often preceded by the sensation of an urge-to-cough (e.g., tickle or itch) at the level of the throat. Self-report of receiving the following assessments for current cough symptoms with unremarkable results: Physical evaluation by at least one physician. Chest x-ray. Willingness to avoid other potential cough treatments during the course of the study (or alert study personnel if alternative treatment is implemented out of necessity). Exclusion Criteria: Current smoker of any substance. Diagnosis of any of the following: Respiratory disease (e.g., chronic obstructive pulmonary disease, asthma) Neurogenic disease (e.g., Parkinson's disease, cerebrovascular disease) Head and neck cancer Self-report of difficulty swallowing since having chronic cough Use of the following medication: Angiotensin-converting enzyme inhibitor (ACE-I) in the past four weeks: benzapril (Lotensin), Captopril (Capoten), Enalapril/Enalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik). Use of a neuromodulator medication in the past 48 hours: Neurontin (Gabapentin) and amitriptyline. Individuals with dysphonia (abnormal voice; either self-reported or perceived by study personnel during enrollment interview) will be excluded unless they have had a normal laryngoscopy (endoscopic assessment of the larynx) by an otolaryngologist (ENT) within the past year specifically for their cough.
Sites / Locations
- University of MontanaRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Sham Comparator
Internet-Behavioral Cough Suppression Therapy
Sham Treatment
Participants will watch treatment-specific educational and training videos and perform the training exercises as recommended. There are a total of five videos ranging from 2-5 minutes in length. Participants will be asked to watch the videos at least once weekly. Daily training exercises will be discussed in the videos and should take no more than a few minutes to complete every day. All exercises are non-invasive and are not physically demanding. Each week participants will complete a progress check question that will take less than one minute to answer, indicating whether they are watching the videos and completing the exercises as recommended.
Participants will watch sham treatment-specific educational and training videos and perform the training exercises as recommended. There are a total of five videos ranging from 2-5 minutes in length. Participants will be asked to watch the videos at least once weekly. Daily training exercises will be discussed in the videos and should take no more than a few minutes to complete every day. All exercises are non-invasive and are not physically demanding. Each week participants will complete a progress check question that will take less than one minute to answer, indicating whether they are watching the videos and completing the exercises as recommended.